Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02900352 · ClinicalTrials.gov registry record · Phase 3
Zonisamide Treatment of Alcohol Use Disorder: an Evaluation of Efficacy and Mechanism of Action
A Phase 3 study of Alcohol Use Disorder, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 3
- Development phase
- 156
- Enrollment target
- 4
- Study locations
NCT02900352: Completed Phase 3 study of Alcohol Use Disorder, sponsored by Virginia Commonwealth University.
NCT02900352 is a Phase 3 study of Alcohol Use Disorder that has completed, run by Virginia Commonwealth University. The registered enrollment target is 156 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (52% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02900352, a Phase 3 study of Alcohol Use Disorder, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 156 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a randomized, placebo-controlled, double-blind, 16 week trial of the medication zonisamide for the treatment of heavy drinking alcoholic civilians.
Primary Outcome
Difference between groups in the number of total standard drinks per week over 8 weeks (weeks 9-16, the weeks on the target dose) performed using a mixed models longitudinal analysis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Zonisamide
Study Locations (4)
Connecticut
- UCONN Health - Farmington
- Yale University - New Haven
- West Haven Veterans Affairs - West Haven
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2016-10 |
| Est. Completion | 2021-04-22 |
| Phase | Phase 3 |
What the finished NCT02900352 record still lists
NCT02900352 is an interventional study that assigns participants to a tested intervention. The registered 156 participants enrollment target is mid-sized for trials with a published cap, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (52% lower).
The record links to 1 condition, with Alcohol Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02900352 reports a single indexed study location in Connecticut, Virginia.
Frequently Asked Questions
What is clinical trial NCT02900352 about?
NCT02900352 is a clinical study titled "Zonisamide Treatment of Alcohol Use Disorder: an Evaluation of Efficacy and Mechanism of Action". This is a randomized, placebo-controlled, double-blind, 16 week trial of the medication zonisamide for the treatment of heavy drinking alcoholic civilians.
What is the current status of trial NCT02900352?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 156 participants. The study started on 2016-10. Estimated completion is 2021-04-22.
What conditions does trial NCT02900352 study?
This clinical trial studies the following conditions: Alcohol Use Disorder.
What interventions are being tested in trial NCT02900352?
The interventions under investigation include: Placebo (DRUG), Zonisamide (DRUG).
Who is sponsoring clinical trial NCT02900352?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02900352 being conducted?
This trial has 4 study locations across Connecticut, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02900352's enrollment target sits among peer trials
156 61st of 184 higher than 124 of 184 other Alcohol Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcohol Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Brenipatide in Participants With Alcohol Use Disorder
RECRUITING · Phase 3
-
Emergency Department-Initiated Medications for Alcohol Use Disorder
RECRUITING · Phase 3
-
Electronic Harm Reduction Treatment for Alcohol
RECRUITING · Phase 3
-
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
RECRUITING · Phase 3
-
Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking
RECRUITING · Phase 2
-
Ultrasound Neuromodulation of the Brain for Alcohol Use Disorder
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03082755 · 156 participants · Phase 4
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
- NCT04047628 · 156 participants · Phase 3
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
- NCT04166877 · 156 participants · Phase 4
Magnesium Infusion for Pain Management in Critically Ill Trauma Patients
- NCT04533464 · 156 participants · Phase 2
MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia